Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study

John K. Geisse, Phoebe Rich, Amit Pandya, Kenneth Gross, Kara Andres, Angie Ginkel, Mary Owens

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5% cream for sBCC to find the most effective frequency of dosing with tolerable side effects. Methods: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. Results: Complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. Conclusion: Imiquimod 5% cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles.

Original languageEnglish (US)
Pages (from-to)390-398
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume47
Issue number3
DOIs
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

imiquimod
Basal Cell Carcinoma
Therapeutics
Safety
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma : A double-blind, randomized, vehicle-controlled study. / Geisse, John K.; Rich, Phoebe; Pandya, Amit; Gross, Kenneth; Andres, Kara; Ginkel, Angie; Owens, Mary.

In: Journal of the American Academy of Dermatology, Vol. 47, No. 3, 01.09.2002, p. 390-398.

Research output: Contribution to journalArticle

Geisse, John K. ; Rich, Phoebe ; Pandya, Amit ; Gross, Kenneth ; Andres, Kara ; Ginkel, Angie ; Owens, Mary. / Imiquimod 5% cream for the treatment of superficial basal cell carcinoma : A double-blind, randomized, vehicle-controlled study. In: Journal of the American Academy of Dermatology. 2002 ; Vol. 47, No. 3. pp. 390-398.
@article{cce4eff63d6a478b9e2f7f2bbb578b65,
title = "Imiquimod 5{\%} cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study",
abstract = "Background: Imiquimod 5{\%} cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5{\%} cream for sBCC to find the most effective frequency of dosing with tolerable side effects. Methods: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. Results: Complete response rates were 100{\%} (10/10), 87.1{\%} (27/31), 80.8{\%} (21/26), and 51.7{\%} (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8{\%} (6/32) in the vehicle group. Conclusion: Imiquimod 5{\%} cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles.",
author = "Geisse, {John K.} and Phoebe Rich and Amit Pandya and Kenneth Gross and Kara Andres and Angie Ginkel and Mary Owens",
year = "2002",
month = "9",
day = "1",
doi = "10.1067/mjd.2002.126215",
language = "English (US)",
volume = "47",
pages = "390--398",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Imiquimod 5% cream for the treatment of superficial basal cell carcinoma

T2 - A double-blind, randomized, vehicle-controlled study

AU - Geisse, John K.

AU - Rich, Phoebe

AU - Pandya, Amit

AU - Gross, Kenneth

AU - Andres, Kara

AU - Ginkel, Angie

AU - Owens, Mary

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5% cream for sBCC to find the most effective frequency of dosing with tolerable side effects. Methods: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. Results: Complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. Conclusion: Imiquimod 5% cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles.

AB - Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies. Objective: The objective of this phase II dose-response study was to explore various dosing regimens using imiquimod 5% cream for sBCC to find the most effective frequency of dosing with tolerable side effects. Methods: Patients (n = 128) were dosed twice daily, once daily, 5 times a week, or 3 times a week in this 12-week, randomized, double-blind, vehicle-controlled study. At 6 weeks after treatment, the entire tumor area was clinically evaluated, excised, and examined exhaustively for histologic evidence of residual sBCC. Results: Complete response rates were 100% (10/10), 87.1% (27/31), 80.8% (21/26), and 51.7% (15/29) for patients in the twice daily, once daily, 5 times a week, and 3 times a week imiquimod groups, respectively, and 18.8% (6/32) in the vehicle group. Conclusion: Imiquimod 5% cream was effective in the treatment of sBCC. Daily or 5 times a week dosing for 12 weeks demonstrated high efficacy results with acceptable safety profiles.

UR - http://www.scopus.com/inward/record.url?scp=0036737628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036737628&partnerID=8YFLogxK

U2 - 10.1067/mjd.2002.126215

DO - 10.1067/mjd.2002.126215

M3 - Article

C2 - 12196749

AN - SCOPUS:0036737628

VL - 47

SP - 390

EP - 398

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -